Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Abeona Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 15
Venture Financing 15
Abeona Therapeutics Raises USD3.6 Million in Venture Financing 15
Abeona Therapeutics Raises US$0.75 Million In Seed Financing 16
Partnerships 17
Abeona Therapeutics Partners with EB Research Partnership and EB Medical Research Foundation 17
Abeona Therapeutics Enters into Partnership Agreement with University of Nebraska Medical Center 18
Licensing Agreements 19
Abeona Therapeutics Enters into Licensing Agreement with RegenxBio 19
Abeona Therapeutics Enters into Licensing Agreement with University of North Carolina at Chapel Hill 20
Abeona Therapeutics Enters into Licensing Agreement with Stanford University 21
Abeona Therapeutics Enters into Licensing Agreement with Stanford University 22
PlasmaTech Biopharma Enters into Licensing Agreement with University of Minnesota 23
PlasmaTech Biopharma Enters into Licensing Agreement with UNeMed 24
Access Pharma Enters into Licensing Agreement with Plasma Technologies 25
PlasmaTech Biopharma Expands Licensing Agreement with Norgine for MuGard 26
Access Pharma Enters into Licensing Agreement with Norgine for MuGard 27
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 28
Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 29
Equity Offering 30
Abeona Therapeutics Plans to Raise USD500 Million in Public Offering of Securities 30
Abeona Therapeutics Raises USD92 Million in Public Offering of Shares 31
Abeona Therapeutics Raises USD44 Million in Public Offering of Shares 33
Abeona Therapeutics Raises USD42 Million in Public Offering of Shares 35
Abeona Therapeutics Raises USD15.6 Million in Private Placement of Shares 37
Abeona Therapeutics Raises USD4.6 Million in Private Placement of Shares up on Exercise of Warrants 38
PlasmaTech Biopharma Raises USD10 Million in Private Placement of Shares 39
PlasmaTech Biopharma Raises USD7 Million in Private Placement of Shares 40
PlasmaTech Biopharma Raises USD14 Million in Public Offering of Shares and Warrants 41
Access Pharma Completes Private Placement Of Units For US$4.7 Million 43
Access Pharma Files Registration Statement For Public Offering Of Units 44
Acquisition 45
PlasmaTech Biopharma Acquires Abeona Therapeutics 45
Abeona Therapeutics Inc – Key Competitors 46
Abeona Therapeutics Inc – Key Employees 47
Abeona Therapeutics Inc – Locations And Subsidiaries 48
Head Office 48
Other Locations & Subsidiaries 48
Recent Developments 49
Strategy And Business Planning 49
Oct 04, 2017: Abeona Therapeutics Announces Dedication of Commercial Gene Therapy Manufacturing Facility in Cleveland, Ohio 49
Financial Announcements 50
Aug 09, 2018: Abeona Therapeutics reports second quarter 2018 financial results and business highlights 50
May 11, 2018: Abeona Therapeutics Reports First Quarter 2018 Financial Results and Business Highlights 52
Mar 16, 2018: Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights 54
Nov 15, 2017: Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights 55
Aug 15, 2017: Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights 56
May 16, 2017: Abeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights 58
Mar 31, 2017: Abeona Therapeutics Reports Q4 2016 Financial Results and Business Highlights 60
Corporate Communications 62
Jul 26, 2018: Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer 62
May 14, 2018: Abeona Therapeutics Announces Appointment of Stefano Buono and Richard Van Duyne to its Board of Directors 63
Apr 02, 2018: Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer 64
Jul 25, 2017: Abeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer 65
Legal and Regulatory 66
Feb 23, 2017: Abeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit 66
Government and Public Interest 67
Oct 16, 2017: Abeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies 67
Product News 68
12/20/2017: Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB 68
Jul 26, 2018: Abeona Therapeutics Announces Leadership Appointments with Max Colao as Chief Commercial Officer 69
05/17/2018: Abeona Reports Update from EB-101 Gene Therapy in Epidermolysis Bullosa at 21st Annual ASGCT Meeting 70
05/12/2017: Abeona Therapeutics Announces Top-Line Data for ABO-102 Phase 1/2 MPS IIIA Gene Therapy Trial at ASGCT 71
05/09/2017: Abeona Therapeutics Receives Regulatory Approval to Initiate Clinical Trial in Australia with ABO-102 Gene Therapy For Patients with MPS IIIA 72
05/08/2017: Abeona Therapeutics Announces Gene Therapy Clinical Trial and Preclinical Program Presentations at ASGCT 20th Annual Meeting 73
05/02/2017: Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosa from the Society for Investigative Dermatology Conference 74
04/25/2017: Abeona Therapeutics Announces EB-101 Clinical Update to be Presented at the Society for Investigative Dermatology Annual Meeting 76
02/17/2017: Abeona Therapeutics Provides Update from ABO-102 Phase 1/2 MPS IIIA Clinical Trial at the 13th Annual WORLDSymposium 2017 78
02/07/2018: Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial 80
02/07/2017: Abeona Therapeutics Presents Data on ABO-102 at the 13th Annual WORLDSymposium 2017 82
02/07/2017: Abeona Therapeutics Presents Data on ABO-201 at the 13th Annual WORLDSymposium 2017 83
02/01/2017: Abeona Therapeutics Enrolls First High Dose Subject in Ongoing Phase 1/2 Gene Therapy Clinical Trial in Sanfilippo Syndrome Type A 84
Product Approvals 85
May 30, 2017: Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa 85
May 25, 2017: Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa 87
Mar 08, 2017: Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101 Gene Therapy Clinical Trial for Epidermolysis Bullosa 88
Jan 19, 2017: Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B 89
Jan 03, 2017: Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-201 Gene Therapy Program in Juvenile Batten Disease 90
Clinical Trials 91
Jan 29, 2018: Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa 91
Aug 29, 2017: Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa 92
Aug 17, 2017: Abeona Therapeutics Provides Update on EB-101 at R&D Day on October 11, 2017 93
Aug 16, 2017: Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A 94
Jul 18, 2017: Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa 95
Appendix 96
Methodology 96
About GlobalData 96
Contact Us 96
Disclaimer 96
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Abeona Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Abeona Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Abeona Therapeutics Raises USD3.6 Million in Venture Financing 15
Abeona Therapeutics Raises US$0.75 Million In Seed Financing 16
Abeona Therapeutics Partners with EB Research Partnership and EB Medical Research Foundation 17
Abeona Therapeutics Enters into Partnership Agreement with University of Nebraska Medical Center 18
Abeona Therapeutics Enters into Licensing Agreement with RegenxBio 19
Abeona Therapeutics Enters into Licensing Agreement with University of North Carolina at Chapel Hill 20
Abeona Therapeutics Enters into Licensing Agreement with Stanford University 21
Abeona Therapeutics Enters into Licensing Agreement with Stanford University 22
PlasmaTech Biopharma Enters into Licensing Agreement with University of Minnesota 23
PlasmaTech Biopharma Enters into Licensing Agreement with UNeMed 24
Access Pharma Enters into Licensing Agreement with Plasma Technologies 25
PlasmaTech Biopharma Expands Licensing Agreement with Norgine for MuGard 26
Access Pharma Enters into Licensing Agreement with Norgine for MuGard 27
Access Pharma Enters Into Licensing Agreement With Amag Pharma For MuGard 28
Access Pharma Enters Into Licensing Agreement With Hanmi Pharma For MuGard 29
Abeona Therapeutics Plans to Raise USD500 Million in Public Offering of Securities 30
Abeona Therapeutics Raises USD92 Million in Public Offering of Shares 31
Abeona Therapeutics Raises USD44 Million in Public Offering of Shares 33
Abeona Therapeutics Raises USD42 Million in Public Offering of Shares 35
Abeona Therapeutics Raises USD15.6 Million in Private Placement of Shares 37
Abeona Therapeutics Raises USD4.6 Million in Private Placement of Shares up on Exercise of Warrants 38
PlasmaTech Biopharma Raises USD10 Million in Private Placement of Shares 39
PlasmaTech Biopharma Raises USD7 Million in Private Placement of Shares 40
PlasmaTech Biopharma Raises USD14 Million in Public Offering of Shares and Warrants 41
Access Pharma Completes Private Placement Of Units For US$4.7 Million 43
Access Pharma Files Registration Statement For Public Offering Of Units 44
PlasmaTech Biopharma Acquires Abeona Therapeutics 45
Abeona Therapeutics Inc, Key Competitors 46
Abeona Therapeutics Inc, Key Employees 47
Abeona Therapeutics Inc, Subsidiaries 48
List of Figures
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Abeona Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Abeona Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 12